Xenon Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : So a little bit of a housekeeping question for me to start. Did the Phase 3 X-TOLE2 trial complete enrollment?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : How are you thinking about what is a win in that data set versus a home run in terms of safety, tolerability and also efficacy? And really, what attributes of those data do you think drive more or less adoption of the product?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : You talked a little bit about this already here, but I think just to put a little bit of a finer point on it, what are you hearing really from the patients in terms of what they're looking for in a new treatment option? And does that deviate at all from what prescribers might be looking for?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : Yeah. And I think, like a follow-up for me on this is just as you think about -- zooming ahead to the product being available, like where do you think physicians are in terms of the awareness of the product today, the class overall? Where do you think that needs to ultimately get to by the time you're ready to launch?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : A question we often get from investors is how does this launch, Tess? So how do you respond to that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:45PM, XENE.OQ - Xenon Pharmaceuticals Inc at JPMorgan Healthcare Conference

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : How does the product launch?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : Helpful, thank you. So switching gears now to the product in MDD. Can you talk a little bit about how confident you are in kind of mitigating some of the key risks that we all know well inherent in these types of studies? What were those kind of key activities that you've been working on over 2024 and into 2025 to try and mitigate those key risks?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : And just in the last couple of minutes here, can you just talk a little bit about, for the broader pipeline at Xenon, where you think the greatest opportunities are? And how should we be thinking about those preclinical programs moving into the clinic in terms of cadence and give us a little bit of a framework?

Question: Tessa Romero - J.P. Morgan Securities LLC - Analyst : All right. Great. Well, thank you for joining us, everyone. I hope you have a great rest of the conference.